-
公开(公告)号：WO2018098270A1
公开(公告)日：2018-05-31
申请号：PCT/US2017/063004
申请日：2017-11-22
发明人： WANG, Guangdi , LIU, Jiawang , ZHENG, Shilong , GUO, Shanchun
IPC分类号： C07F5/02 , A61K31/69 , A61K31/56 , C07C235/56 , C07C255/60
CPC分类号： C07F5/025 , C07C235/56 , C07C255/60 , C07J43/003 , C07J51/00
摘要： The present disclosure relates to androgen receptor signaling inhibitors and the synthesis of the same. Further, the present disclosure teaches the utilization of the androgen receptor signaling inhibitors in a treatment for proliferative diseases, including cancer, particularly prostate cancer, and especially castration-resistant prostate cancer.
-
公开(公告)号：WO2018102261A3
公开(公告)日：2018-06-07
申请号：PCT/US2017/063322
申请日：2017-11-27
发明人： WANG, Guangdi , ZHENG, Shilong , LIU, Jiawang , ZHONG, Qiu , GUO, Shanchun
摘要： The present disclosure relates to boronic derivatives of hydroxamate compounds, methods for making the same, methods for use as a monotherapy or in combination with one or more other therapeutic agents, for treatment of proliferative diseases such as cancer. The present disclosure also teaches the utilization of said boronic derivatives of hydroxamate s as epigenetic therapy medications with enhanced bioavailability, lower-toxicity, and longer-lasting efficacy.
-
3.发明申请BORON-BASED PRODRUG STRATEGY FOR INCREASED BIOAVAILABILITY AND LOWER-DOSAGE REQUIREMENTS FOR DRUG MOLECULES CONTAINING AT LEAST ONE PHENOL (OR AROMATIC HYDROXYL) GROUP 审中-公开基于BORON的PRODRUG策略，用于提高生物利用度和降低至少一种苯酚（或芳族羟基）基团的药物分子的需求
公开(公告)号：WO2016004166A1
公开(公告)日：2016-01-07
申请号：PCT/US2015/038768
申请日：2015-07-01
发明人： WANG, Guangdi , ZHONG, Qiu , ZHENG, Shilong
IPC分类号： C07F5/02 , C07C233/07 , C07D311/04 , C07D417/12 , C07D403/12 , C07D501/20
摘要： Boron-based prodrugs of phenol- or aromatic hydroxyl group -containing therapeutic molecules ("original drugs"), uses thereof, and methods of making the same, are provided for achieving, for example, improved bioavailability, prolonged retention (e.g., in a circulatory system) and, in particular, significantly lowered therapeutically effective dosage in order to reduce adverse effects while maintaining the desired therapeutic effects of the original drugs.
摘要翻译： 提供含苯酚或芳香族羟基的治疗分子（“原始药物”）的基于硼的前药，其用途及其制备方法用于实现例如改善的生物利用度，延长的保留（例如， 循环系统），特别是显着降低治疗有效剂量，以便在保持原始药物的期望治疗效果的同时减少不良反应。
-
4.发明申请ANTI-VASCULATURE AND ANTI-TUBULIN COMBRETASTATIN ANALOGS FOR TREATMENT OF CANCER 审中-公开用于治疗癌症的抗血管和抗血管肽化合物类似物
公开(公告)号：WO2015153252A1
公开(公告)日：2015-10-08
申请号：PCT/US2015/022624
申请日：2015-03-26
发明人： WANG, Guangdi , ZHENG, Shilong , ZHONG, Qiu , ZHANG, Qiang
IPC分类号： C07D213/30 , C07D213/61 , A61K31/4418 , A61P35/00
CPC分类号： C07D213/61 , A61K31/4418 , A61K31/4425 , A61K45/06 , C07D213/30
摘要： Combretastatins analog compounds and their pharmaceutically acceptable salts are presented, as well as pharmaceutical compositions comprising the combretastatin analog compounds and uses of the combretastatin analog compounds, either alone or in combination with at least one additional therapeutic agent, in the treatment of cancer, and in particular cancer presenting as metastatic tumors.
摘要翻译： 本发明提供了组合复方及其药学上可接受的盐，以及包含考布他汀类似物化合物的药物组合物，以及考丁胺汀类似物化合物的单独使用或与至少一种其它治疗剂组合用于治疗癌症， 特定的癌症呈现为转移性肿瘤。
-
公开(公告)号：WO2018102261A2
公开(公告)日：2018-06-07
申请号：PCT/US2017/063322
申请日：2017-11-27
发明人： WANG, Guangdi , ZHENG, Shilong , LIU, Jiawang , ZHONG, Qiu , GUO, Shanchun
CPC分类号： C07F5/025
摘要： The present disclosure relates to boronic derivatives of hydroxamate compounds, methods for making the same, methods for use as a monotherapy or in combination with one or more other therapeutic agents, for treatment of proliferative diseases such as cancer. The present disclosure also teaches the utilization of said boronic derivatives of hydroxamate s as epigenetic therapy medications with enhanced bioavailability, lower-toxicity, and longer-lasting efficacy.
-
公开(公告)号：WO2017192991A1
公开(公告)日：2017-11-09
申请号：PCT/US2017/031297
申请日：2017-05-05
发明人： WANG, Guangdi , LIU, Jiawang , ZHENG, Shilong , ZHONG, Qiu , GUO, Shanchun
摘要： The present disclosure relates to orally bioavailable selective estrogen receptor down-regulators (SERDs) and the synthesis of the same. Further, the present disclosure teaches the utilization of the orally bioavailable selective estrogen receptor down-regulators (SERDs) in a treatment for proliferative diseases, including cancer, particularly breast cancer, and especially ER+ breast cancer.
摘要翻译： 本公开涉及口服生物可利用的选择性雌激素受体下调（SERD）及其合成。 此外，本公开教导了口服生物利用选择性雌激素受体下调（SERD）在治疗增殖性疾病（包括癌症，特别是乳腺癌，特别是ER +乳腺癌）中的应用。
-
7.发明申请ANTI-MIGRATION AND ANTI-INVASION THIAZOLE ANALOGS FOR TREATMENT OF CELLULAR PROLIFERATIVE DISEASE 审中-公开用于治疗细胞增殖性疾病的抗移植和抗入侵噻唑类似物
公开(公告)号：WO2014052831A1
公开(公告)日：2014-04-03
申请号：PCT/US2013/062302
申请日：2013-09-27
发明人： ZHENG, Shilong , WANG, Guangdi , JIANG, Quan , ZHONG, Qiu , ZHANG, Qiang
IPC分类号： C07D277/38 , C07D417/12 , A61K31/426 , A61K31/427 , A61P35/00
CPC分类号： C07D417/12 , A61K31/426 , A61K31/427 , A61K31/4439 , A61K45/06 , C07D277/40 , C07D277/44 , C07D277/46 , C07D277/52 , A61K2300/00
摘要： Thiazole analog compounds and their pharmaceutically acceptable salts are disclosed, including pharmaceutical compositions comprising the thiazole analog compounds, either alone or in combination with at least one additional therapeutic agent, and/or with a pharmaceutically acceptable carrier. Methods of using the thiazole analog compounds, either alone or in combination with at least one additional therapeutic agent, in the prophylaxis or treatment of cellular proliferative diseases, such as cancer, are also disclosed.
摘要翻译： 公开了噻唑类似物及其药学上可接受的盐，包括单独或与至少一种另外的治疗剂组合的包含噻唑类似物化合物的药物组合物和/或药学上可接受的载体。 还公开了单独或与至少一种另外的治疗剂组合使用噻唑类似物化合物在预防或治疗细胞增殖性疾病如癌症中的方法。
-
-
-
-
-
-
搜索结果
7 条记录 (耗时 0.016 秒)
